Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong operating and pipeline evidence: Q2 2026 net product revenue rose about 55% YoY to $243.6M, management raised 2026 revenue guidance to $980M-$995M, and positive KPL-387 Phase 2 data supports the pipeline. The stock is up about 25% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠High Margins ⢠Low Debt KNSA is financially strong with high margins, ample liquidity, low debt, and solid cash flow, but its elevated valuation and accumulated losses make the shares appear expensive.
Price Behavior
Key Price Behavior Insights: ⢠Mild downtrend ⢠Failed rebound ⢠Key range Support Level: $76.25â$76.50; stronger support $75.15 Resistance Level: $79.33â$80.47 KNSA remains technically cautious after slipping last month and failing to hold its rebound, with support at $76.25â$76.50 and resistance at $79.33â$80.47.
Sentiment & News
Key News Insights: ⢠Arcalyst sales ⢠Pipeline progress ⢠Investor outreach Kiniksa's 41% rally reflects Arcalyst-driven momentum and pipeline optimism, reinforced by active investor engagement.
AI Summary
KNSA is now a profitable, cash-generative specialty-pharma company, but at ~77x earnings and with ARCALYST driving nearly all value, investors should wait for sustained penetration-driven growth or a more attractive entry point while treating KPL-387 as upside optionalityânot a proven second engine.
Description
Kiniksa Pharmaceuticals is a biopharmaceutical company that discovers, acquires, develops and commercializes therapies for patients with serious conditions lacking adequate treatment options. Its portfolio includes an approved interleukin-1 therapy for recurrent pericarditis and several monoclonal antibody candidates in clinical development for inflammatory and immune-mediated diseases. The company was incorporated in 2015 and is headquartered in Hamilton, Bermuda.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 30 | Aug 6 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Strong operating and pipeline evidence: Q2 2026 net product revenue rose about 55% YoY to $243.6M, management raised 2026 revenue guidance to $980M-$995M, and positive KPL-387 Phase 2 data supports the pipeline. The stock is up about 25% over 21 trading days. | Closed | -2.2% |
| Apr 29 | May 6 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Q1 2026 beat expectations with EPS of $0.27 vs. $0.18 expected, ARCALYST revenue rose 56% YoY to $214.3M, 2026 ARCALYST revenue guidance was raised to $930M-$945M, and the stock is trading near 52-week highs. | Closed | +9.9% |